Lofgren et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa500 (preprint 9/21) (Peer Reviewed) (not included in the study count) Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
Analysis of 2,795 outpatients not showing significant safety concerns with HCQ. No deaths were related to HCQ. There was one serious event requiring hospitalization, identical to the frequency with placebo.
Lofgren et al., 9/21/2020, peer-reviewed, 26 authors.